Developing new services through joint research with universities and specialists
First written in FY2022. 8 of 10 entries say "Restated". Latest entry: FY2026-H1.
2 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「Total R&D expenses for the interim accounting period were ¥23 million.」
The company continued its R&D activities and disclosed R&D expenses of ¥23 million for the interim accounting period. - FY2025AdvancedAnnual report
「In April 2024, we also established the joint research program “PD Long-Term Observation Joint Research Program.” …As a result, total R&D expenses for the fiscal year were ¥59 million.」
The PD Long-Term Observation Joint Research Program was established in April 2024. Research into data-based care and home adaptation progressed, and R&D expenses totaled ¥59 million. - FY2025-H1RestatedAnnual report
「Our total R&D expenses for the six-month period were ¥22 million.」
R&D activities continued, with R&D expenses of ¥22 million for the six-month period. - FY2024RestatedAnnual report
「As a result, total R&D expenses for the fiscal year were ¥21 million.」
Joint research and system validation with Juntendo University and others continued, and annual R&D expenses were ¥21 million. - FY2024-Q3RestatedAnnual report
「Our total R&D expenses for the cumulative nine-month period were ¥18 million.」
R&D activities continued, with R&D expenses of ¥18 million for the cumulative nine-month period. - FY2024-Q2RestatedAnnual report
「Our total R&D expenses for the cumulative six-month period were ¥11 million.」
R&D activities continued, with R&D expenses of ¥11 million for the cumulative six-month period. - FY2024-Q1RestatedAnnual report
「Our total R&D expenses for the cumulative three-month period were ¥4 million.」
R&D activities continued, with R&D expenses of ¥4 million for the cumulative three-month period. - FY2023-Q3RestatedAnnual report
「Our total R&D expenses for the cumulative nine-month period were ¥16 million.」
R&D activities continued, with R&D expenses of ¥16 million for the cumulative nine-month period. - FY2023-Q2RestatedAnnual report
「Our total R&D expenses for the cumulative six-month period were ¥12 million.」
R&D activities continued, with R&D expenses of ¥12 million for the cumulative six-month period. - FY2022First statedAnnual report
「With Juntendo University, we established a joint research program and are validating a three-dimensional online medical consultation system and activity detection using wearable devices, as well as conducting online seminars.」
Research with Juntendo University, Fukuoka University and Hokkaido Neurosurgical Hospital covers online medical consultations, wearable devices, dance and VR rehabilitation. R&D expenses were ¥23 million.